Shilpa Medicare
Shilpa Medicare Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth. Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.
From Shilpa Medicare's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth.
- Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income.
- Launches like NorUDCA and transdermal Rotigotine to boost revenues.
- Biologics and Formulation segments anticipated to drive higher growth; API segment to grow steadily.
- Increased utilization and new oral solid line at formulation plant to support revenue ramp-up.
- Oncology business expected to grow with resolved product validations and increased capacity.
- CDMO peptide facility launching with ~INR40 crore capex, expecting inquiries and scale-up.
- Licensing income stable at ~INR150 crores annually, with quarter-to-quarter variations normal.
2 more points from Shilpa Medicare's call on revenue
Every concall, every company
Profitability & Margins
See what Shilpa Medicare said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New peptide capacity planned with a capex of around INR 40 crores to cater to growing GLP-1 peptide demand and CDMO opportunities (Page 13).
- Investment in a new oral solid formulation line recently commissioned to support upcoming launches and generate additional revenues in FY '27 (Page 15).
- Significant past capex completed; current focus is on execution, scaling, and maximizing ROCE from existing investments (Page 6).
- Capex of about INR 87 crores incurred during Q3 FY '26, with expectation to mainly fund capex through internal accruals (Page 6).
2 more points from Shilpa Medicare's call on capex
Every concall, every company
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shilpa Medicare said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- NorUDCA launch has been very successful, exceeding expectations with a strong order book as of Q3 FY26.
- Good traction in NorUDCA is noted with an expanding order book from the three marketing partners.
- For oncology and other products, specific order book numbers were not disclosed due to confidentiality.
- Formulation segment shows stable base revenue, with Europe at ~INR73 crores indicating a steady order flow.
2 more points from Shilpa Medicare's call on order book
Every concall, every company
Shilpa Medicare — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹437 Cr, net profit ₹108 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shilpa Medicare's management said in earlier quarters
Arthneeti Pro · Annual
Shilpa Medicare and 1,500+ more calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shilpa Medicare Q3 FY26 results?
FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth. Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.
What is Shilpa Medicare share price analysis?
Shilpa Medicare currently shows a neutral. The stock trades at a P/E of 56.0 with a market cap of ₹15,939 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shilpa Medicare planning capital expenditure?
New peptide capacity planned with a capex of around INR 40 crores to cater to growing GLP-1 peptide demand and CDMO opportunities (Page 13).
Keep Shilpa Medicare on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.